Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
← catalyst calendarNCT07089121 · readout ≤ 499 d
Sponsored by Cartesian Therapeutics (industry) · RNAC — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
50estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-14 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Childhood-onset Systemic Lupus Erythematous
- ANCA-Associated Vasculitis (AAV)
- Juvenile Myasthenia Gravis
- Juvenile Dermatomyositis
Intervention
- Drug: Descartes-08
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2
measured Days 22 and 50 for Part1 , Days 22, 50 and Months 3,6,9 and 12 for part 2
Maximum Dose Tolerated
measured Days 2250 for Part 1, Days 11,50, month 3 for part 2 in addition to months, 4,6,9,12
Permalink · RNAC's whole pipeline · Catalyst calendar · Every registered study · What changed